NEUROBLASTOMA

This early-stage trial tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma had stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. Researchers also …

This study tested a new daily pill called lorlatinib in 65 children and young adults with a type of nerve cancer (neuroblastoma) that had come back or not responded to treatment. The drug targets a specific genetic change in the cancer cells. The main goals were to find the safes…

This early-phase study tested a treatment for children with high-risk neuroblastoma that had come back or not responded to standard therapy. The approach combined a radioactive drug (131I-MIBG) that targets tumor cells with two chemotherapy drugs (irinotecan and vincristine). The…

This early-stage study tested a type of radiation therapy called PRRT in one child with neuroblastoma that had come back or not responded to standard treatments. The therapy uses a radioactive drug that targets tumor cells. The main goal was to find the safest dose and monitor si…

This study tested whether adding an immunotherapy drug (Hu3F8) plus GM-CSF to standard treatment could stop high-risk neuroblastoma from returning in children who had already achieved remission. Fifty-nine children participated. The goal was to see how long they stayed cancer-fre…

This early-phase study tested whether immune cells called natural killer (NK) cells, taken from the patient's own blood and boosted in a lab, could be safely given back to children and young adults with solid tumors that didn't respond to standard treatments. Sixteen participants…

This study tested a new antibody (hu14.18K322A) added to standard chemotherapy for 153 children with high-risk neuroblastoma, a serious nerve cell cancer. The goal was to see if the combination could shrink tumors and improve survival. While the treatment aims to control the dise…

This study tested a new treatment for children with high-risk neuroblastoma, a type of cancer. Researchers took the children's own immune cells (T cells) and modified them to better recognize and attack cancer cells. Some of these cells were also trained to fight a common virus t…

This early-phase trial tested a two-part radioactive treatment (I-MIBG) followed by a stem cell transplant in 18 children with neuroblastoma that didn't respond to standard therapy. The goal was to find the safest highest dose of radiation that could be given in two quick infusio…

This study tested a new type of stem cell transplant for children and young adults (ages 2-21) with cancers that came back or didn't respond to treatment. The approach uses a special cell filter to speed up immune recovery after transplant. The main goal was to see if the procedu…

This study tested whether a smaller dose of radiation can still control high-risk neuroblastoma while causing fewer long-term side effects. 78 children with high-risk neuroblastoma received reduced-dose radiation to the main tumor site. Researchers tracked how well the cancer was…

This early-phase trial tested an oral powder form of the drug fenretinide in 80 children whose neuroblastoma had come back or not responded to standard treatment. The main goals were to find the safest dose and understand side effects. The study also looked at how the drug moves …

This study looked at whether it's possible to use a child's tumor DNA to choose their next treatment. 186 children with cancers that came back or didn't respond to standard therapy had their tumors analyzed. The goal was to see if this approach could be done quickly enough to gui…